KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
Open Access
- 19 March 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 108 (8), 1757-1764
- https://doi.org/10.1038/bjc.2013.118
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal CancersClinical Cancer Research, 2012
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon CancerJAMA, 2012
- Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectumGut, 2012
- Quality Assessment and Correlation of Microsatellite Instability and Immunohistochemical Markers among Population- and Clinic-Based Colorectal Tumors: Results from the Colon Cancer Family RegistryThe Journal of Molecular Diagnostics, 2011
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancerGut, 2008
- Mutation analysis of 24 known cancer genes in the NCI-60 cell line setMolecular Cancer Therapeutics, 2006
- Mutations of the BRAF gene in human cancerNature, 2002
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001